(Q34585485)

3 August 2017

title

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody (English)

1 reference

3 August 2017

1 reference

Wim K Bleeker

1

1 reference

3 August 2017

Martin E Munk

2

1 reference

3 August 2017

Wendy J M Mackus

3

1 reference

3 August 2017

Jeroen H N van den Brakel

4

1 reference

3 August 2017

Marielle Pluyter

5

1 reference

3 August 2017

Martin J Glennie

6

1 reference

3 August 2017

Jan G J van de Winkel

7

1 reference

3 August 2017

Paul W H I Parren

8

1 reference

3 August 2017

language of work or name

English

0 references

publication date

27 November 2007

1 reference

British Journal of Haematology

3 August 2017

published in

1 reference

3 August 2017

volume

140

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

303-312

1 reference

Potent antibody therapeutics by design

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

Treatment of rheumatoid arthritis with rituximab: an update and possible indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

Signalling antibodies for the treatment of neoplastic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

Renaissance of cancer therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

Selective internalization of monoclonal antibodies by B‐cell chronic lymphocytic leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06916.X

10.1111/J.1365-2141.2007.06916.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference